questionsmedicales.fr
Enzymes et coenzymes
Enzymes
Oxidoreductases
Alcohol oxidoreductases
NAD (+) and NADP (+) dependent Alcohol oxidoreductases
3-Hydroxyacyl-CoA dehydrogenases
Hydroxymethylglutaryl-CoA reductases
Hydroxymethylglutaryl-CoA reductases : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Hydroxymethylglutaryl-CoA reductases : Questions médicales les plus fréquentes",
"headline": "Hydroxymethylglutaryl-CoA reductases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Hydroxymethylglutaryl-CoA reductases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-29",
"dateModified": "2025-03-26",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Hydroxymethylglutaryl-CoA reductases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "3-Hydroxyacyl-CoA dehydrogenases",
"url": "https://questionsmedicales.fr/mesh/D015094",
"about": {
"@type": "MedicalCondition",
"name": "3-Hydroxyacyl-CoA dehydrogenases",
"code": {
"@type": "MedicalCode",
"code": "D015094",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.047.820.150"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Hydroxymethylglutaryl-CoA reductases, NAD-dependent",
"alternateName": "Hydroxymethylglutaryl-CoA Reductases, NAD-Dependent",
"url": "https://questionsmedicales.fr/mesh/D025781",
"about": {
"@type": "MedicalCondition",
"name": "Hydroxymethylglutaryl-CoA reductases, NAD-dependent",
"code": {
"@type": "MedicalCode",
"code": "D025781",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.047.820.150.415.250"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Hydroxymethylglutaryl-CoA reductases, NADP-dependent",
"alternateName": "Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent",
"url": "https://questionsmedicales.fr/mesh/D025782",
"about": {
"@type": "MedicalCondition",
"name": "Hydroxymethylglutaryl-CoA reductases, NADP-dependent",
"code": {
"@type": "MedicalCode",
"code": "D025782",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.047.820.150.415.750"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Hydroxymethylglutaryl-CoA reductases",
"alternateName": "Hydroxymethylglutaryl CoA Reductases",
"code": {
"@type": "MedicalCode",
"code": "D006903",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Russell A DeBose-Boyd",
"url": "https://questionsmedicales.fr/author/Russell%20A%20DeBose-Boyd",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, Texas 75390-9046, USA."
}
},
{
"@type": "Person",
"name": "Youngah Jo",
"url": "https://questionsmedicales.fr/author/Youngah%20Jo",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, Texas 75390-9046, USA."
}
},
{
"@type": "Person",
"name": "George Davey Smith",
"url": "https://questionsmedicales.fr/author/George%20Davey%20Smith",
"affiliation": {
"@type": "Organization",
"name": "Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom."
}
},
{
"@type": "Person",
"name": "Hiromasa Yoshioka",
"url": "https://questionsmedicales.fr/author/Hiromasa%20Yoshioka",
"affiliation": {
"@type": "Organization",
"name": "Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113 0032, Japan."
}
},
{
"@type": "Person",
"name": "Kenji Ohgane",
"url": "https://questionsmedicales.fr/author/Kenji%20Ohgane",
"affiliation": {
"@type": "Organization",
"name": "Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113 0032, Japan. Electronic address: ohgane@rs.tus.ac.jp."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Introducing the trier univalence neutrality ambivalence (TUNA) database: A picture database differentiating complex attitudes.",
"datePublished": "2024-05-16",
"url": "https://questionsmedicales.fr/article/38753714",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0302904"
}
},
{
"@type": "ScholarlyArticle",
"name": "KID: A Kinase-Focused Interaction Database and Its Application in the Construction of Kinase-Focused Molecule Databases.",
"datePublished": "2022-11-29",
"url": "https://questionsmedicales.fr/article/36447388",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.jcim.2c00908"
}
},
{
"@type": "ScholarlyArticle",
"name": "DrugMechDB: A Curated Database of Drug Mechanisms.",
"datePublished": "2023-09-16",
"url": "https://questionsmedicales.fr/article/37717042",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41597-023-02534-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "CSD Communications of the Cambridge Structural Database.",
"datePublished": "2023-01-01",
"url": "https://questionsmedicales.fr/article/36598498",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1107/S2052252522010545"
}
},
{
"@type": "ScholarlyArticle",
"name": "Big data: Using databases and registries.",
"datePublished": "2022-09-23",
"url": "https://questionsmedicales.fr/article/36414357",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1053/j.semvascsurg.2022.09.002"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D010088"
},
{
"@type": "ListItem",
"position": 5,
"name": "Alcohol oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D000429"
},
{
"@type": "ListItem",
"position": 6,
"name": "NAD (+) and NADP (+) dependent Alcohol oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D064430"
},
{
"@type": "ListItem",
"position": 7,
"name": "3-Hydroxyacyl-CoA dehydrogenases",
"item": "https://questionsmedicales.fr/mesh/D015094"
},
{
"@type": "ListItem",
"position": 8,
"name": "Hydroxymethylglutaryl-CoA reductases",
"item": "https://questionsmedicales.fr/mesh/D006903"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Hydroxymethylglutaryl-CoA reductases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Hydroxymethylglutaryl-CoA reductases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-05",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Hydroxymethylglutaryl-CoA reductases",
"description": "Comment diagnostiquer une dysfonction des réductases ?\nQuels examens sont recommandés pour évaluer les réductases ?\nLes tests génétiques sont-ils utiles ?\nQuels symptômes indiquent un problème avec les réductases ?\nComment évaluer l'activité des réductases ?",
"url": "https://questionsmedicales.fr/mesh/D006903?mesh_terms=Databases,+Factual&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Hydroxymethylglutaryl-CoA reductases",
"description": "Quels sont les symptômes d'une hypercholestérolémie ?\nComment se manifeste une maladie liée aux réductases ?\nY a-t-il des signes cutanés associés ?\nLes symptômes sont-ils toujours présents ?\nQuels autres symptômes peuvent survenir ?",
"url": "https://questionsmedicales.fr/mesh/D006903?mesh_terms=Databases,+Factual&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Hydroxymethylglutaryl-CoA reductases",
"description": "Comment prévenir les problèmes liés aux réductases ?\nLe tabagisme influence-t-il les réductases ?\nL'alcool a-t-il un impact sur le cholestérol ?\nLes contrôles médicaux réguliers sont-ils importants ?\nQuels aliments privilégier pour la santé des réductases ?",
"url": "https://questionsmedicales.fr/mesh/D006903?mesh_terms=Databases,+Factual&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Hydroxymethylglutaryl-CoA reductases",
"description": "Quels médicaments sont utilisés pour traiter les dysfonctionnements ?\nY a-t-il des traitements non médicamenteux ?\nComment les statines agissent-elles ?\nLes traitements sont-ils efficaces à long terme ?\nQuels effets secondaires peuvent survenir ?",
"url": "https://questionsmedicales.fr/mesh/D006903?mesh_terms=Databases,+Factual&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Hydroxymethylglutaryl-CoA reductases",
"description": "Quelles complications peuvent survenir avec une dyslipidémie ?\nComment l'athérosclérose est-elle liée aux réductases ?\nLes maladies hépatiques sont-elles une complication ?\nQuels risques cardiovasculaires sont associés ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D006903?mesh_terms=Databases,+Factual&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Hydroxymethylglutaryl-CoA reductases",
"description": "Quels sont les principaux facteurs de risque ?\nL'hérédité joue-t-elle un rôle ?\nLe stress influence-t-il les niveaux de cholestérol ?\nL'âge est-il un facteur de risque ?\nLes maladies chroniques influencent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D006903?mesh_terms=Databases,+Factual&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction des réductases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins mesurant les niveaux de cholestérol et des enzymes hépatiques sont effectués."
}
},
{
"@type": "Question",
"name": "Quels examens sont recommandés pour évaluer les réductases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une échographie abdominale et des tests de fonction hépatique peuvent être recommandés."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils utiles ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent identifier des mutations génétiques affectant les réductases."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un problème avec les réductases ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de cholestérol et des maladies cardiovasculaires peuvent indiquer un problème."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'activité des réductases ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques spécifiques peuvent mesurer l'activité des hydroxyméthylglutaryl-CoA réductases."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une hypercholestérolémie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des douleurs thoraciques, fatigue et problèmes cardiaques."
}
},
{
"@type": "Question",
"name": "Comment se manifeste une maladie liée aux réductases ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut se manifester par des dépôts de cholestérol dans les artères et des douleurs."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cutanés associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des xanthomes peuvent apparaître, indiquant une accumulation de lipides."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils toujours présents ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, certains patients peuvent être asymptomatiques malgré des niveaux élevés de cholestérol."
}
},
{
"@type": "Question",
"name": "Quels autres symptômes peuvent survenir ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles de la vision et des douleurs abdominales peuvent également se manifester."
}
},
{
"@type": "Question",
"name": "Comment prévenir les problèmes liés aux réductases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et l'exercice régulier aident à maintenir un bon cholestérol."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il les réductases ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme augmente le risque de dyslipidémie et de maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "L'alcool a-t-il un impact sur le cholestérol ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une consommation excessive d'alcool peut aggraver les niveaux de cholestérol."
}
},
{
"@type": "Question",
"name": "Les contrôles médicaux réguliers sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils permettent de détecter précocement les anomalies du cholestérol."
}
},
{
"@type": "Question",
"name": "Quels aliments privilégier pour la santé des réductases ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les aliments riches en fibres, comme les fruits et légumes, sont bénéfiques."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour traiter les dysfonctionnements ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les statines sont couramment prescrites pour réduire le cholestérol sanguin."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements non médicamenteux ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des changements de mode de vie comme l'alimentation et l'exercice sont recommandés."
}
},
{
"@type": "Question",
"name": "Comment les statines agissent-elles ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles inhibent l'hydroxyméthylglutaryl-CoA réductase, réduisant ainsi la production de cholestérol."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces à long terme ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, avec un suivi régulier, les traitements peuvent maintenir des niveaux de cholestérol sains."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent survenir ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs musculaires et des troubles digestifs sont des effets secondaires possibles."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une dyslipidémie ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent les maladies cardiaques, les AVC et l'athérosclérose."
}
},
{
"@type": "Question",
"name": "Comment l'athérosclérose est-elle liée aux réductases ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une production excessive de cholestérol due à des réductases dysfonctionnelles peut provoquer l'athérosclérose."
}
},
{
"@type": "Question",
"name": "Les maladies hépatiques sont-elles une complication ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une accumulation de lipides peut entraîner des maladies hépatiques comme la stéatose."
}
},
{
"@type": "Question",
"name": "Quels risques cardiovasculaires sont associés ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux élevés de cholestérol augmentent le risque de crises cardiaques et d'AVC."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié et des changements de mode de vie."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'obésité, le tabagisme, l'inactivité physique et une mauvaise alimentation."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de dyslipidémie augmentent le risque de problèmes liés aux réductases."
}
},
{
"@type": "Question",
"name": "Le stress influence-t-il les niveaux de cholestérol ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut contribuer à des niveaux de cholestérol élevés."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de dyslipidémie augmente avec l'âge, surtout après 45 ans."
}
},
{
"@type": "Question",
"name": "Les maladies chroniques influencent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maladies comme le diabète augmentent le risque de dyslipidémie et de complications."
}
}
]
}
]
}
Using validated stimulus material is crucial for ensuring research comparability and replicability. However, many databases rely solely on bidimensional valence ratings, ranging from negative to posit...
Protein kinases are important drug targets for the treatment of several diseases. The interaction between kinases and ligands is vital in the process of small-molecule kinase inhibitor (SMKI) design. ...
Computational drug repositioning methods have emerged as an attractive and effective solution to find new candidates for existing therapies, reducing the time and cost of drug development. Repositioni...
The Cambridge Structural Database (CSD) is a collection of over one million experimental three-dimensional structures obtained through crystallographic analyses. These structures are determined by cry...
The field of vascular surgery is in constant evolution. Administrative data and registries can provide important contemporary evidence to inform clinical decision making and delivery of health service...
Cancer is a subject of extensive investigation, and the utilization of omics technology has resulted in the generation of substantial volumes of big data in cancer research. Numerous databases are bei...
Compound databases (DBs) are essential tools for drug discovery. The number of DBs in public domain is increasing, so it is important to analyze these DBs. In this article, the main characteristics of...
Knowledge of hazards and exposure data about chemical pollutants are essential for epidemiological studies for assessing health risks and preventing the development of diseases. Access to this type of...
This paper presents the creation of an online inventory of toxicological and exposure DBs to support human health risk assessment resulting from the chemical exposome....
A free searchable online inventory, called TEDI (Toxicological and Exposure Database Inventory), was set up to collect meta-data on toxicological and exposure DBs resulting from a review of the litera...
A total of 715 DBs were identified, catalogued, described and made available on TEDI. The number of chemicals ranged from one single chemical to 90 million for toxicological DBs and from 1 to 103,817 ...
TEDI is of value to the broader community and could support human health risk assessment to chemicals in various contexts. This inventory remains open for further additions, to enlarge its coverage, i...
The Reaction Mechanism Generator (RMG) database for chemical property prediction is presented. The RMG database consists of curated datasets and estimators for accurately predicting the parameters nec...
For a single species, human kinship organization is both remarkably diverse and strikingly organized. Kinship terminology is the structured vocabulary used to classify, refer to, and address relatives...